A consortium of investors led by LSP has backed a €67m series-A round for Alizé Pharma 3, a French company developing treatments for rare endocrine and metabolic diseases.
Gyrus is fundraising for both its open-ended Cortex Fund and closed-ended Principal Fund
Fund targets companies operating in a wide range of sectors and deploys tickets in the $50-500m range
Predecessor vehicle PEC III closed on $389m in October 2017 and is now fully deployed
Arlington expects to put fresh capital into the business and grow it through acquisitions